Cargando…
Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib
Although the therapeutic benefit of proteasome inhibition in multiple myeloma remains unchallenged, drug resistance inevitably emerges through mechanisms that remain elusive. Bortezomib provokes unwanted protein accumulation and the endoplasmic reticulum stress to activate the unfolded protein respo...
Autores principales: | Jagannathan, S, Abdel-Malek, M A Y, Malek, E, Vad, N, Latif, T, Anderson, K C, Driscoll, J J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635337/ https://www.ncbi.nlm.nih.gov/pubmed/26108695 http://dx.doi.org/10.1038/leu.2015.157 |
Ejemplares similares
-
Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma
por: Abdel Malek, Mohamed A.Y., et al.
Publicado: (2014) -
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma
por: Malek, E, et al.
Publicado: (2017) -
Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017) -
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib
por: Jagannathan, S, et al.
Publicado: (2015) -
High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib
por: Malek, Ehsan, et al.
Publicado: (2016)